Here is the recording of the latest AS 101 webinar. Newly diagnosed patients with prostate cancer often ask if there is a particular diet plan they should follow. Stacy Loeb, MD, a professor in the Department of Urology at NYU Grossman School of Medicine addresses diet and other lifestyle questions in the newest segment of AS 101, an ongoing “college-like” course to help these newly diagnosed patients. Be sure to visit the ASPI (Active Surveillance Patients International ) website to stay up to date with the AS 101 series. Watch it here
Dr. Laurence Klotz, of the University of Toronto, is known as the father of active surveillance. But he has been involved in other advances in prostate care since the mid-1990s, including focal therapy. Who is the right candidate for focal? Should a 4+3 or higher ever consider focal (AnCan always navigates away for these guys) Is every 3+4 a candidate? What about high-volume Gleason 6 patients? Are all focal therapies born equal? If you have Gleason 4 in your gland, how can you be assured it has not micro-spread within the gland? Should you only get focal therapy from a Center of Excellence? How do
November 2022 Awareness Night Dr. Olivier Heimrath, MD FRCSC Staff Urologist, Humber River Hospital Associate Urologist, Michael Garron Hospital Lecturer, University of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:31:31 Disclaimer: The contents of this video is solely for the purposes of education and information and does not constitute personal diagnostic advice or personal medical advice.
The TULSA ablation treatment is a focal therapy for the ablation of a surgeon defined region of prostate while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. Read about it here. TULSA was invented at Sunnybrook, and Dr. Klotz was involved in the development and evaluation of the technology over the last 20 years. The TULSA team he has assembled is one of the most experienced in the world. Click here for more information.
July 2022 Awareness Night Dr. Di (Maria) Jiang, MD, Msc, FRCPC Staff Oncologist, Genitourinary Group Princess Margaret Cancer Centre, UHN Asst Prof., Clinician Investigator, Dept of Medicine, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:33:48 Disclaimer: The contents of this video is solely for the purposes of education and information and does not constitute personal diagnostic advice or personal medical advice.
March 2022 Awareness Night Dr Darryl Leong, MBBS(Hons), MPH, M.Biostat, PhD, FRACP, FESC Director, McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University Staff Cardiologist, Hamilton Health Sciences.McMaster. CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:18:44 Disclaimer: The contents of this video is solely for the purposes of education and information and does not constitute personal diagnostic advice or personal medical advice.
January 2022 Awareness Night Dr Danny Vesprini, B.Sc, M.Sc, MD, FRCPC Dept. of radiation oncology, Sunnybrook Health Sciences Centre, Toronto Affiliate scientist, Biological Sciences, , Sunnybrook Research Institute Assistant professor, Dept. of radiation oncology, University of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 1:54:42 Disclaimer: The contents of this video is solely for the purposes of education and information and does not constitute personal diagnostic advice or personal medical advice.
Thousands of men with prostate cancer in the UK could be cured with an hour-long operation, doctors hope. The ‘game-changing’ treatment uses electrical currents to destroy difficult to reach tumours. Read the article.
On July 29, 2021, Drs. Ming Zhou, Pathologist-in-Chief and Chair of Anatomic and Clinical Pathology, Tufts Medical School, and Dr. Scott Eggener, Vice Chair of Urology at the University of Chicago, debated this question: Is Gleason 6 a cancer? The doctors presented their cases at the AnCan program in this video individually. One of Eggener’s key points is that he has never seen a patient die from Gleason 6 so why call it a cancer. Zhou took the stand that if it looks like a cancer, which Gleason does under the microscope, then it’s a cancer. The question-and-answer period covered such
Video is now available of the fourth webinar in Us TOO‘s series, What is Right for Me in My Prostate Cancer Treatment?, a discussion on Imaging. Continuing advances in imaging technology and usage can mean more accurate testing and diagnosis related to prostate cancer, and can help guide patients toward the best treatment options for them. Hear the latest from the experts on this very important topic. This webinar was recorded on June 24th. View the Video here. Featuring: Brian T. Helfand MD, PhD – Chief, Division of Urology, Ronald L. Chez Family and Richard Melman Family Endowed Chair of